Marshall & Sullivan Inc. WA trimmed its holdings in Danaher Co. (NYSE:DHR) by 3.4% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 36,552 shares of the conglomerate’s stock after selling 1,289 shares during the period. Danaher accounts for approximately 3.7% of Marshall & Sullivan Inc. WA’s holdings, making the stock its 5th largest position. Marshall & Sullivan Inc. WA’s holdings in Danaher were worth $5,224,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of DHR. Next Capital Management LLC acquired a new position in Danaher during the 2nd quarter valued at $31,000. Litman Gregory Asset Management LLC acquired a new position in Danaher during the 2nd quarter valued at $33,000. Lenox Wealth Management Inc. acquired a new position in Danaher during the 1st quarter valued at $40,000. Capital Advisors Ltd. LLC raised its stake in Danaher by 527.5% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 320 shares of the conglomerate’s stock valued at $46,000 after purchasing an additional 269 shares during the last quarter. Finally, Contravisory Investment Management Inc. acquired a new position in Danaher during the 2nd quarter valued at $69,000. Institutional investors and hedge funds own 79.49% of the company’s stock.

Danaher stock traded down $0.10 on Wednesday, hitting $139.97. The company’s stock had a trading volume of 39,230 shares, compared to its average volume of 2,103,424. The company has a fifty day moving average price of $141.20 and a 200-day moving average price of $131.85. The company has a quick ratio of 1.91, a current ratio of 2.32 and a debt-to-equity ratio of 0.33. Danaher Co. has a one year low of $94.59 and a one year high of $145.50. The firm has a market cap of $100.68 billion, a P/E ratio of 30.97, a price-to-earnings-growth ratio of 2.53 and a beta of 0.94.

Danaher (NYSE:DHR) last posted its earnings results on Thursday, July 18th. The conglomerate reported $1.19 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.15 by $0.04. Danaher had a net margin of 12.22% and a return on equity of 11.53%. The business had revenue of $5.16 billion for the quarter, compared to analyst estimates of $5.09 billion. During the same quarter in the prior year, the firm earned $1.15 EPS. The firm’s quarterly revenue was up 3.5% compared to the same quarter last year. Analysts anticipate that Danaher Co. will post 4.79 EPS for the current year.

In other news, insider Brian W. Ellis sold 1,010 shares of the company’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $144.04, for a total value of $145,480.40. Following the sale, the insider now owns 20,889 shares of the company’s stock, valued at approximately $3,008,851.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CAO Robert S. Lutz sold 14,668 shares of the company’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $143.28, for a total transaction of $2,101,631.04. Following the completion of the sale, the chief accounting officer now directly owns 21,054 shares in the company, valued at approximately $3,016,617.12. The disclosure for this sale can be found here. In the last ninety days, insiders sold 354,316 shares of company stock worth $48,598,531. 11.40% of the stock is owned by insiders.

Several equities analysts recently commented on DHR shares. Argus upped their target price on shares of Danaher to $165.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Needham & Company LLC reiterated a “buy” rating and set a $155.00 target price (up from $142.00) on shares of Danaher in a research note on Friday, July 19th. Royal Bank of Canada set a $134.00 target price on shares of Danaher and gave the company a “hold” rating in a research note on Friday, July 19th. Robert W. Baird boosted their price target on shares of Danaher from $131.00 to $148.00 and gave the company an “outperform” rating in a report on Friday, July 19th. Finally, Wolfe Research initiated coverage on shares of Danaher in a report on Thursday, May 30th. They issued an “outperform” rating on the stock. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $143.54.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.

Featured Story: Bear Market

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.